INTRON a interferon

Intron A interferon a-2b Schering-Plough Hairy cell leukemia, genital warts, AIDS-related Kaposi s sarcoma, hepatitis C, hepatitis B, malignant melanoma, follicular lymphoma in conjunction with chemotherapy... [Pg.694]

A. General description Intron A (interferon alfa-2b recombinant) is a recombi-nantly derived water-soluble protein with a molecular weight of 19.3 kDa. It is obtained from the bacterial fermentation of a strain of Escherichia coli bearing a genetically engineered plasmid containing an interferon alfa-2b gene from human leukocytes. [Pg.192]

E. Therapeutic response A randomized trial compared treatment with PEG-Intron, once weekly, to treatment with Intron A (interferon alfa-2b), three times weekly, in 1219 previously untreated adults with chronic hepatitis from HCV infection. Patients were treated for 48 weeks. Response to treatment was defined as undetectable HCV RNA (less than 100 copies per ml) and normalization of the liver enzyme alanine aminotransferase (ALT) at 24 weeks post-treatment. Response rates to the l.Opg/kg PEG-Intron doses and to Intron A were 24% and 12%. Patients receiving PEG-Intron with viral genotype 1 had a response rate of 14%, while patients with other viral genotypes had a 45% response rate. [Pg.206]

REBETOL (Ribavirin) and INTRON A (interferon alfa-2b) [E. coli-expressed recombinant protein]... [Pg.326]

Biogen/Roche Intron A (interferon a-2b) Hepatitis B and C Expired Expired (France) 2007 (Italy)... [Pg.190]

Intron A Interferon-a Schering-Plough Hepatitis/lymphoid tumors 2000... [Pg.69]

Intron A Interferon alfa-2 Schering-Plough 6/1986 Hairy cell leukemia/genital warts/AIDS-related E. coli... [Pg.1423]

Blenoxane - bleomycin Intron-A - interferon alfa-2b Stilphostrol - diethylstilbestrol... [Pg.395]

Intron A interferon alpha-2b Schering-Plough C Alpha interferon 1360... [Pg.726]

The subcutaneous dose of interferon alfa-2b (Intron A) in patients who are HBsAg-positive is either 5 million units daily (better tolerated) or 10 million units three times weekly. The dose for HBsAg-negative patients is 5 to 6 million units three times weekly. The approved dose for pegylated interferon alfa-2a (Pegasys) for chronic hepatitis B is 180 meg subcutaneously once weekly. Interferon doses may need to be adjusted in patients with renal impairment. [Pg.354]

Interferon alfa-2a (Roferon A), interferon alfa-2b (Intron-A), and interferon alfacon-1 (Infergen) are approved for chronic hepatitis C. However, they are not prescribed alone because only 12% to 16% of patients achieve a sustained virologic response (SVR). Adding ribavirin, a synthetic guanosine analogue that inhibits viral polymerase, increases the SVR rate to 35% to 45%. [Pg.356]

Interferon alfa-2a Interferon alfa-2b 18 million IU 18 million IU 209.58 218.04 Roferon-A Intron-A ... [Pg.185]

Interferon-a-2b Intron A Schering Plough Expired Expired... [Pg.354]

Intron A (Sobering Plough) Interferon-a (treatment of leukaemia) 1.4... [Pg.11]

Interferons a-2b (Intron-A), a-nl, and a-n3 (Alferon N) have both intrinsic antiviral effects and antiproliferative and immunomodulatory actions. These interferons are approved for intralesional therapy of refractory or recurrent condylomata (genital warts). Toxicities include flulike symptoms, nausea, depression of the white blood cell count, and mild diminution in hematocrit. [Pg.492]

Interferon alfa-2b (Intron A) is a recombinant DNA product derived from the interferon alfa-2b gene of human white blood cells. Its mechanism of antitumor action involves binding to a plasma membrane receptor but is otherwise poorly understood. Its serum half-life is 2 to 3 hours after parenteral administration. [Pg.652]

E. Therapeutic response Efficacy of Infergen therapy was determined by measurement of serum alanine aminotransferase (ALT) concentrations at the end of therapy (24 weeks) and following 24 weeks of observation after the end of treatment of adults with chronic HCV infection. Serum HCV RNA was also assessed using a quantitative reverse transcriptase polymerase chain reaction (RT-PCR). At the end of 24 weeks of treatment, ALT normalization was observed in 39% of patients on Infergen and in 35% of patients on interferon alfa-2b Intron A). Only 17% of patients in each group... [Pg.189]

Drug Interactions According to the product label, interactions between Intron A and other drugs have not been fully evaluated. Caution should be exercised when administering Intron A therapy in combination with other potentially myelo-suppressive agents such as zidovudine. Concomitant use of alfa interferon and theophylline decreases theophylline clearance, resulting in a 100% increase in serum theophylline levels. [Pg.193]

Interferons and cytokines Interferon alfa-2b, human recombinant product produced in E. coli Intron A Lyophilized 5, 10,18,25, or 50MIUvial IM,SC, IV, intralesional... [Pg.461]

Interferons and cytokines Peginterferon aha-2b, PEG-modified human recombinant inteferon alfa-2b (Intron A, produced in E. coh) PEG-Intron Lyophilized 74,118,177, or 222 ig in 2 ml vial sc... [Pg.462]

Parenteral 3, 6, 9, 36 million IU vials Interferon alfa-2b (Intron A)... [Pg.1089]

Aerosol (Virazole) powder to reconstitute for aerosol 6 g/100 ml vial Oral (Rebetol, generic) 200 mg capsules, tablets 40 mg/mLoral solution Oral (Rebetron) 200 mg in combination with 3 million units interferon alfa-2b (Intron-A) Rifabutin (Mycobutin)... [Pg.1090]

Drug(s) Biologic response modifiers Interferons Interferon alfa-2a [Roferon-A] Interferon alfa-2b [Intron-A] Primary Antineoplastic Indication(s) Hairy-cell leukemia Kaposi sarcoma chronic myelocytic leukemia renal and bladder cancers Common Adverse Effects Flulike syndrome [mild fever, chills, malaise]... [Pg.578]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...